---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188117"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:37:17.076881+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apellis reports 6 retinal vasculitis events after SYFOVRE; rate ~0.01% per injection

## Summary
- Six retinal vasculitis events observed after first SYFOVRE injection, 7-13 days post-dose; no specific lot implicated.
- Estimated event rate ~1 per 10,000 injections (0.01%); approximately 60,000 vials distributed since FDA approval.
- Two events confirmed occlusive, one non-occlusive, three undetermined; etiology unclear, outcomes evolving.
- Zero retinal vasculitis events in clinical trials (>23,000 injections); FDA notified, no action planned at this time.
- Company investigating with ASRS ReST Committee and external specialists; will update as new info emerges.

## SEC filing metadata
- accession: 0001193125-23-188117
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523188117/0001193125-23-188117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523188117/d510143d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188117
- JSON: https://secwatch.observer/filing/0001193125-23-188117.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.